07:00 , May 30, 2011 |  BC Week In Review  |  Clinical News

Genasense oblimersen sodium injection: Additional Phase III data

Additional data from the double-blind, international Phase III AGENDA trial in 314 patients showed that IV Genasense plus dacarbazine missed the co-primary endpoint of significantly improving median OS vs. placebo plus dacarbazine (13.5 vs. 13.1...
08:00 , Nov 8, 2010 |  BioCentury  |  Finance

Wanted: Less Dilution

The $1 billion in therapeutic tax credit money doled out by the U.S. Treasury last week was spread so thinly among 3,000 companies that biotech CEOs are already looking at ways to make a hoped-for...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Clinical News

Genasense oblimersen: Updated Phase II data

Updated data from an ongoing, open-label, U.S. Phase II trial in 10 evaluable patients with advanced melanoma showed that 900 mg IV Genasense twice weekly for 4 weeks plus Temodar temozolomide and Abraxane paclitaxel produced...
08:00 , Jan 4, 2010 |  BioCentury  |  Finance

Whole lotta nothin'

The wins last quarter were few and far between, while there were several clinical and regulatory blow-ups ranging from the largest to the smallest cap companies. With the exception of a 4% gain for the...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Clinical News

Genasense oblimersen sodium injection): Preliminary Phase II data

Preliminary data from an ongoing, open-label, U.S. Phase II trial in 10 patients with stage IV metastatic melanoma showed that 900 mg IV Genasense twice weekly for 4 weeks plus Temodar temozolomide and Abraxane paclitaxel...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

Genasense oblimersen sodium injection: Additional Phase III data

Additional data from the double-blind, international Phase III AGENDA trial in 314 patients showed that Genasense plus dacarbazine (DTIC) led to a median PFS of 2.8 months vs. 2.7 months for placebo plus DTIC (p=0.23)....
08:00 , Nov 2, 2009 |  BC Week In Review  |  Clinical News

Genasense oblimersen sodium injection: Phase III data

Top-line data from the double-blind, international Phase III AGENDA trial in 314 patients showed that Genasense plus dacarbazine (DTIC) missed the co-primary endpoint of a significant improvement in PFS vs. placebo plus DTIC. Genta said...
07:00 , Jun 1, 2009 |  BioCentury  |  Regulation

Accelerated approvals in CLL

Accelerated approvals in CLL...
07:00 , May 25, 2009 |  BC Week In Review  |  Clinical News

Genasense injection oblimersen sodium: Phase III ongoing

Genta said an independent data monitoring board recommended continuation of the double-blind, placebo-controlled, international Phase III AGENDA trial based on planned analyses for safety and futility based on PFS. The study is evaluating 7 mg/kg/day...
07:00 , Apr 13, 2009 |  BC Week In Review  |  Clinical News

Genasense oblimersen sodium injection: Completed Phase III enrollment

Genta completed enrollment of 315 patients in the double-blind, placebo-controlled, international Phase III AGENDA trial evaluating 7 mg/kg/day of IV Genasense given for the first 5 days of a 21-day cycle for up to 8...